losartan has been researched along with Pain in 13 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Camurati-Engelmann Disease (CED) is a rare sclerosing bone disease, sometimes associated delayed puberty." | 6.82 | Improvement of Bone Health and Initiation of Puberty Development in Camurati-Engelmann Disease With Glucocorticoid and Losartan Treatment: A Case Report and Review of Literature. ( Cui, L; Guan, W; Jiang, Y; Li, Q; Li, X; Xia, W; Yu, W, 2022) |
| "Treatment with losartan was initiated at a daily dose of 0." | 5.40 | Elimination of pain and improvement of exercise capacity in Camurati-Engelmann disease with losartan. ( Ayyavoo, A; Cutfield, WS; Derraik, JG; Hofman, PL, 2014) |
| "Both the angiotensin converting enzyme inhibitor enalapril and the AT1 receptor blocking agent losartan acted similarly on pain threshold and tolerance, pain sensitivity being increased during the two anti-hypertensive treatments." | 5.10 | Changes in pain perception during treatment with angiotensin converting enzyme-inhibitors and angiotensin II type 1 receptor blockade. ( Diolisi, A; Garganico, D; Gaudio, G; Grandi, AM; Guasti, L; Simoni, C; Venco, A; Zanotta, D, 2002) |
| " Losartan (Los) is known to reduce pain; however, its function in IBS is unclear." | 4.31 | Losartan attenuates acetic acid enema-induced visceral hypersensitivity by inhibiting the ACE1/Ang II/AT1 receptor axis in enteric glial cells. ( Chen, Y; Dai, F; Li, J; Li, L; Liu, X; Mei, L; Meng, R; Quan, X; Shi, H; Sun, Y; Wang, J; Wang, L; Wang, T; Zhang, Y, 2023) |
| " Delayed exercise after complex orthopaedic trauma results in decreased muscle fibrosis and improved pain Losartan, an angiotensin-receptor blocker with anti-fibrotic abilities, recapitulates the effect of exercise on post-injury recovery and may provide an enhanced recovery option for those who are unable to exercise after injury ABSTRACT: Chronic pain and disability after limb injury are major public health problems." | 3.96 | Angiotensin receptor blockade mimics the effect of exercise on recovery after orthopaedic trauma by decreasing pain and improving muscle regeneration. ( Clark, JD; Forman, TE; Goodman, SB; Paine, P; Pajarinen, J; Quarta, M; Rando, TA; Takemura, Y; Tawfik, VL, 2020) |
| "Camurati-Engelmann Disease (CED) is a rare sclerosing bone disease, sometimes associated delayed puberty." | 2.82 | Improvement of Bone Health and Initiation of Puberty Development in Camurati-Engelmann Disease With Glucocorticoid and Losartan Treatment: A Case Report and Review of Literature. ( Cui, L; Guan, W; Jiang, Y; Li, Q; Li, X; Xia, W; Yu, W, 2022) |
| "Camurati-Engelmann disease (CED) is a rare autosomal dominant disease." | 1.91 | Proband and the Brother. ( B, S; Kotha, JP, 2023) |
| "Treatment with losartan was initiated at a daily dose of 0." | 1.40 | Elimination of pain and improvement of exercise capacity in Camurati-Engelmann disease with losartan. ( Ayyavoo, A; Cutfield, WS; Derraik, JG; Hofman, PL, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 6 (46.15) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, L | 1 |
| Li, Q | 1 |
| Guan, W | 1 |
| Yu, W | 1 |
| Li, X | 1 |
| Xia, W | 1 |
| Jiang, Y | 1 |
| Sriwatananukulkit, O | 2 |
| Desclaux, S | 2 |
| Tawonsawatruk, T | 2 |
| Srikuea, R | 2 |
| Himakhun, W | 2 |
| Likitnukul, S | 2 |
| Hemstapat, R | 2 |
| Sun, Y | 1 |
| Liu, X | 1 |
| Wang, L | 1 |
| Li, L | 1 |
| Quan, X | 1 |
| Shi, H | 1 |
| Wang, T | 1 |
| Mei, L | 1 |
| Chen, Y | 1 |
| Zhang, Y | 1 |
| Li, J | 1 |
| Meng, R | 1 |
| Wang, J | 1 |
| Dai, F | 1 |
| B, S | 1 |
| Kotha, JP | 1 |
| Tawfik, VL | 1 |
| Quarta, M | 1 |
| Paine, P | 1 |
| Forman, TE | 1 |
| Pajarinen, J | 1 |
| Takemura, Y | 1 |
| Goodman, SB | 1 |
| Rando, TA | 1 |
| Clark, JD | 1 |
| Hadipour-Lakmehsari, S | 1 |
| Al Mouaswas, S | 1 |
| Ayyavoo, A | 1 |
| Derraik, JG | 1 |
| Cutfield, WS | 1 |
| Hofman, PL | 1 |
| Costa, AC | 1 |
| Romero, TR | 1 |
| Pacheco, DF | 1 |
| Perez, AC | 1 |
| Savernini, A | 1 |
| Santos, RR | 1 |
| Duarte, ID | 1 |
| Nemoto, W | 1 |
| Ogata, Y | 1 |
| Nakagawasai, O | 1 |
| Yaoita, F | 1 |
| Tanado, T | 1 |
| Tan-No, K | 1 |
| Pelegrini-da-Silva, A | 1 |
| Rosa, E | 1 |
| Guethe, LM | 1 |
| Juliano, MA | 1 |
| Prado, WA | 1 |
| Martins, AR | 1 |
| Krohn, J | 1 |
| Bjune, C | 1 |
| Georgieva, D | 1 |
| Georgiev, V | 1 |
| Guasti, L | 1 |
| Zanotta, D | 1 |
| Diolisi, A | 1 |
| Garganico, D | 1 |
| Simoni, C | 1 |
| Gaudio, G | 1 |
| Grandi, AM | 1 |
| Venco, A | 1 |
1 review available for losartan and Pain
| Article | Year |
|---|---|
Improvement of Bone Health and Initiation of Puberty Development in Camurati-Engelmann Disease With Glucocorticoid and Losartan Treatment: A Case Report and Review of Literature.
Topics: Adolescent; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bone Density | 2022 |
1 trial available for losartan and Pain
| Article | Year |
|---|---|
Changes in pain perception during treatment with angiotensin converting enzyme-inhibitors and angiotensin II type 1 receptor blockade.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; D | 2002 |
11 other studies available for losartan and Pain
| Article | Year |
|---|---|
Effectiveness of losartan on infrapatellar fat pad/synovial fibrosis and pain behavior in the monoiodoacetate-induced rat model of osteoarthritis pain.
Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Fibrosis; Iodoacetic Acid; Losarta | 2023 |
Effectiveness of losartan on infrapatellar fat pad/synovial fibrosis and pain behavior in the monoiodoacetate-induced rat model of osteoarthritis pain.
Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Fibrosis; Iodoacetic Acid; Losarta | 2023 |
Effectiveness of losartan on infrapatellar fat pad/synovial fibrosis and pain behavior in the monoiodoacetate-induced rat model of osteoarthritis pain.
Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Fibrosis; Iodoacetic Acid; Losarta | 2023 |
Effectiveness of losartan on infrapatellar fat pad/synovial fibrosis and pain behavior in the monoiodoacetate-induced rat model of osteoarthritis pain.
Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Fibrosis; Iodoacetic Acid; Losarta | 2023 |
Losartan attenuates acetic acid enema-induced visceral hypersensitivity by inhibiting the ACE1/Ang II/AT1 receptor axis in enteric glial cells.
Topics: Acetic Acid; Animals; Enema; Irritable Bowel Syndrome; Lipopolysaccharides; Losartan; Neuroglia; Pai | 2023 |
Proband and the Brother.
Topics: Adult; Camurati-Engelmann Syndrome; Child; Female; Humans; Losartan; Male; Mutation; Pain; Positron | 2023 |
Angiotensin receptor blockade mimics the effect of exercise on recovery after orthopaedic trauma by decreasing pain and improving muscle regeneration.
Topics: Angiotensin Receptor Antagonists; Animals; Fibrosis; Fractures, Bone; Hyperalgesia; Losartan; Mice; | 2020 |
Reduction of pain and improved muscle biology with the administration of losartan and delayed exercise in a murine trauma model.
Topics: Angiotensins; Animals; Losartan; Mice; Orthopedics; Pain; Regeneration | 2020 |
Elimination of pain and improvement of exercise capacity in Camurati-Engelmann disease with losartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Camurati-Engelmann Syndrome; Child; Exercise; Female; Human | 2014 |
Participation of AT1 and Mas receptors in the modulation of inflammatory pain.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Inflammation; Losartan; Male; Mice | 2014 |
The intrathecal administration of losartan, an AT1 receptor antagonist, produces an antinociceptive effect through the inhibiton of p38 MAPK phosphorylation in the mouse formalin test.
Topics: Analgesics; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Injections, Spinal; Lo | 2015 |
Angiotensin III modulates the nociceptive control mediated by the periaqueductal gray matter.
Topics: Analgesics; Angiotensin II; Angiotensin III; Angiotensin Receptor Antagonists; Animals; Disease Mode | 2009 |
Uveal effusion and angle-closure glaucoma in primary pulmonary hypertension.
Topics: Aged; Antihypertensive Agents; Conjunctiva; Corneal Edema; Dilatation, Pathologic; Female; Glaucoma, | 2003 |
The role of angiotensin II and of its receptor subtypes in the acetic acid-induced abdominal constriction test.
Topics: Acetic Acid; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 1999 |